Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H22FN3O2 |
Molecular Weight | 379.4274 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4
InChI
InChIKey=RMEDXOLNCUSCGS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
Molecular Formula | C22H22FN3O2 |
Molecular Weight | 379.4274 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00450Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12190308 |
32.2 nM [IC50] | ||
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2879412 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | INAPSINE Approved UseDroperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date1970 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: |
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Sources: Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) |
2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
QT interval prolonged | Disc. AE | 0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Tremor | 1.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Akathisia | 16.4% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Asthenia | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Somnolence | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Anxiety | 27.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Anorexia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Chills | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Confusion | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Paresthesia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Nervousness | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Pharyngitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Rhinitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Sweaty | 8.2% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Dizziness | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Dry mouth | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Torsades de pointes | Disc. AE | 2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 19.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
major |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients. | 2001 Apr-Jun |
|
[Intraoperative memory. A study of its incidence in general anesthesia in 326 patients]. | 2001 Aug |
|
Variation in practice patterns of anesthesiologists in California for prophylaxis of postoperative nausea and vomiting. | 2001 Aug |
|
Effects of dopamine antagonists in human eye accommodation. | 2001 Feb |
|
Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review. | 2001 Feb |
|
Prevention of postoperative nausea and vomiting with antiemetics in patients undergoing middle ear surgery: comparison of a small dose of propofol with droperidol or metoclopramide. | 2001 Jan |
|
[Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo]. | 2001 Jul |
|
Pediatric renal transplantation: anesthesia and perioperative complications. | 2001 Mar |
|
[Droperidol and dimenhydrinate alone or in combination for prevention of postoperative nausea and vomiting]. | 2001 May |
|
Impact of antiemetic selection on postoperative nausea and vomiting and patient satisfaction. | 2001 May |
|
[Postoperative nausea--still a problem]. | 2001 Oct 3 |
|
[Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy]. | 2002 Jan |
|
[Droperidol causes multifocal ventricular dysrhythmias]. | 2002 Jan |
|
Premedication, preparation, and surveillance. | 2002 Jan |
|
The FDA droperidol warning: is it justified? | 2002 Jul |
|
Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure. | 2002 Jun |
|
Gateways to Clinical Trials. June 2002. | 2002 Jun |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/droperidol.html
Curator's Comment: Intravenous or Intramuscular
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.
Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16492829
Droperidol (10(-7) M) caused vasodilator effect (approximately 20% of vasorelaxation compared with maximal vasorelaxation induced by papaverine [3 x 10(-4) M] in rat vascular smooth muscle cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:55:21 GMT 2025
by
admin
on
Wed Apr 02 07:55:21 GMT 2025
|
Record UNII |
O9U0F09D5X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05AD08
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
CFR |
21 CFR 522.800
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
LIVERTOX |
332
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
NCI_THESAURUS |
C323
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
NDF-RT |
N0000175800
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
NDF-RT |
N0000175799
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
WHO-VATC |
QN05AD08
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
||
|
WHO-ATC |
N01AX01
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D004329
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
966
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
4717
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
DB00450
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
548-73-2
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
208-957-8
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
C458
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
1229001
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
Droperidol
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
Droperidol
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
SUB06410MIG
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
3320
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
3648
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
m4769
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
O9U0F09D5X
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
169874
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
7172
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL1108
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
1609
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
DTXSID6022973
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
100000081007
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
3168
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY | |||
|
O9U0F09D5X
Created by
admin on Wed Apr 02 07:55:21 GMT 2025 , Edited by admin on Wed Apr 02 07:55:21 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||